First Time Loading...
A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 3.23 USD -1.22%
Updated: May 14, 2024

Operating Margin
Aquestive Therapeutics Inc

-37.8%
Current
-77%
Average
7.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-37.8%
=
Operating Profit
-19.5m
/
Revenue
51.5m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Aquestive Therapeutics Inc
NASDAQ:AQST
292.2m USD
-38%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
721B USD
32%
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK
45%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
363.1B USD
28%
US
Merck & Co Inc
NYSE:MRK
325.5B USD
10%
UK
AstraZeneca PLC
LSE:AZN
189.8B GBP
18%
CH
Novartis AG
SIX:NOVN
183.4B CHF
28%
CH
Roche Holding AG
SIX:ROG
178.4B CHF
32%
US
Pfizer Inc
NYSE:PFE
159.4B USD
19%
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Country US
Market Cap 292.2m USD
Operating Margin
-38%
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Eli Lilly and Co
NYSE:LLY
Country US
Market Cap 721B USD
Operating Margin
32%
Novo Nordisk A/S
CSE:NOVO B
Country DK
Market Cap 4.1T DKK
Operating Margin
45%
Dechra Pharmaceuticals PLC
LSE:DPH
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Johnson & Johnson
NYSE:JNJ
Country US
Market Cap 363.1B USD
Operating Margin
28%
Merck & Co Inc
NYSE:MRK
Country US
Market Cap 325.5B USD
Operating Margin
10%
AstraZeneca PLC
LSE:AZN
Country UK
Market Cap 189.8B GBP
Operating Margin
18%
Novartis AG
SIX:NOVN
Country CH
Market Cap 183.4B CHF
Operating Margin
28%
Roche Holding AG
SIX:ROG
Country CH
Market Cap 178.4B CHF
Operating Margin
32%
Pfizer Inc
NYSE:PFE
Country US
Market Cap 159.4B USD
Operating Margin
19%

Profitability Report

View the profitability report to see the full profitability analysis for Aquestive Therapeutics Inc.

Full Profitability Report

See Also

Summary
AQST intrinsic value, competitors valuation, and company profile.
DCF Valuation
AQST stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AQST stock valuation using valuation multiples.
Wall Street Estimates
AQST price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AQST stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-37.8%
=
Operating Profit
-19.5m
/
Revenue
51.5m
What is the Operating Margin of Aquestive Therapeutics Inc?

Based on Aquestive Therapeutics Inc's most recent financial statements, the company has Operating Margin of -37.8%.

ALPHA SPREAD
Join more than 137,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.